Becton, Dickinson and Company $BDX Shares Acquired by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 31.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,824 shares of the medical instruments supplier’s stock after acquiring an additional 432 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Becton, Dickinson and Company were worth $314,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bill Few Associates Inc. boosted its holdings in shares of Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 55 shares during the last quarter. Gilbert & Cook Inc. boosted its stake in Becton, Dickinson and Company by 2.0% in the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after buying an additional 56 shares during the last quarter. Mendel Money Management grew its holdings in Becton, Dickinson and Company by 2.6% in the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock valued at $388,000 after buying an additional 58 shares during the period. Plancorp LLC increased its stake in shares of Becton, Dickinson and Company by 4.1% during the 1st quarter. Plancorp LLC now owns 1,499 shares of the medical instruments supplier’s stock valued at $343,000 after acquiring an additional 59 shares during the last quarter. Finally, Moody National Bank Trust Division lifted its holdings in shares of Becton, Dickinson and Company by 2.4% during the 2nd quarter. Moody National Bank Trust Division now owns 2,586 shares of the medical instruments supplier’s stock worth $445,000 after acquiring an additional 60 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,249 shares of company stock worth $231,358 in the last quarter. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BDX shares. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Morgan Stanley upped their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus lifted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $203.27.

Becton, Dickinson and Company Trading Down 0.1%

NYSE:BDX opened at $192.93 on Friday. The business’s 50-day moving average is $186.66 and its two-hundred day moving average is $181.94. The firm has a market capitalization of $55.30 billion, a PE ratio of 34.70, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.2%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.